1. Home
  2. CMPX vs JYNT Comparison

CMPX vs JYNT Comparison

Compare CMPX & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMPX
  • JYNT
  • Stock Information
  • Founded
  • CMPX 2014
  • JYNT 2010
  • Country
  • CMPX United States
  • JYNT United States
  • Employees
  • CMPX N/A
  • JYNT N/A
  • Industry
  • CMPX Biotechnology: Pharmaceutical Preparations
  • JYNT Multi-Sector Companies
  • Sector
  • CMPX Health Care
  • JYNT Miscellaneous
  • Exchange
  • CMPX Nasdaq
  • JYNT Nasdaq
  • Market Cap
  • CMPX 217.4M
  • JYNT 163.0M
  • IPO Year
  • CMPX N/A
  • JYNT 2014
  • Fundamental
  • Price
  • CMPX $1.71
  • JYNT $11.50
  • Analyst Decision
  • CMPX Strong Buy
  • JYNT Strong Buy
  • Analyst Count
  • CMPX 2
  • JYNT 2
  • Target Price
  • CMPX $9.00
  • JYNT $18.00
  • AVG Volume (30 Days)
  • CMPX 370.5K
  • JYNT 58.2K
  • Earning Date
  • CMPX 11-07-2024
  • JYNT 11-07-2024
  • Dividend Yield
  • CMPX N/A
  • JYNT N/A
  • EPS Growth
  • CMPX N/A
  • JYNT N/A
  • EPS
  • CMPX N/A
  • JYNT N/A
  • Revenue
  • CMPX $850,000.00
  • JYNT $120,071,078.00
  • Revenue This Year
  • CMPX N/A
  • JYNT $0.70
  • Revenue Next Year
  • CMPX $950.68
  • JYNT N/A
  • P/E Ratio
  • CMPX N/A
  • JYNT N/A
  • Revenue Growth
  • CMPX N/A
  • JYNT 7.46
  • 52 Week Low
  • CMPX $0.77
  • JYNT $7.31
  • 52 Week High
  • CMPX $2.34
  • JYNT $17.82
  • Technical
  • Relative Strength Index (RSI)
  • CMPX 71.13
  • JYNT 53.89
  • Support Level
  • CMPX $1.42
  • JYNT $10.80
  • Resistance Level
  • CMPX $1.65
  • JYNT $12.02
  • Average True Range (ATR)
  • CMPX 0.13
  • JYNT 0.40
  • MACD
  • CMPX 0.02
  • JYNT 0.15
  • Stochastic Oscillator
  • CMPX 90.83
  • JYNT 98.43

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.

Share on Social Networks: